Navigation Links
Interim Analysis of Phase I/II Study of Rexin-G Confirms Efficacy With No Dose Limiting Toxicity in Metastatic Pancreatic Cancer
Date:4/21/2008

Second Phase Opens With Higher Dose Regimens

SAN MARINO, Calif., April 21 /PRNewswire/ -- Epeius Biotechnologies Corporation announced today that Interim Analysis of an on-going Phase I/II study of Rexin-G for pancreatic cancer confirmed Rexin-G's anti-tumor activity with no major toxicity in patients with metastatic chemotherapy-resistant pancreatic cancer. The clinical trial design includes 5 escalating doses of intravenous Rexin-G ranging from 1 x 10e11 cfu twice a week to 4 x 10e11 cfu three times a week for 4 weeks. Treatment cycles are repeated if the patient exhibits Grade 1 or less toxicity. Interim analysis showed no dose limiting toxicities in 9 evaluable patients who received Dose Levels 1-3. Furthermore, the analysis showed decrease in tumor size or disease stabilization (by RECIST), decreased metabolic activity in tumors (by PET-CT scan), reduction in tumor marker levels, and clinical benefit in patients receiving Dose Level 3. The second phase of the Rexin-G study has now opened wherein six patients will receive Dose levels 4 and 5, respectively, as the Phase I/II adaptive study design continues to evaluate the over-all safety of Rexin-G and to determine the optimal dosing regimen for Rexin-G that would document the clinical benefits required to support a Phase II/III pivotal trial.

*(LOGO: Send2Press.com/mediaboom/08-0421-Epeius_72dpi.jpg)

According to Dr. Sant P. Chawla, Principal Investigator of the Phase I/II study, "I am happy with the positive results of Rexin-G seen in pancreatic cancer, and look forward to obtaining even better results with progressively higher doses of Rexin-G." Dr. Chawla is currently conducting three Los Angeles-based Phase I/II clinical trials using Rexin-G in sarcoma, pancreatic cancer, and breast cancer, and a Phase II study of Rexin-G for osteosarcoma. For further information concerning these clinical trials, please contact Dr. Erlinda M. Gordon at

SOURCE Epeius Biotechnologies Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Medarex Reports Interim Data from Ongoing Ipilimumab Combination Phase 1 Studies in Prostate Cancer at American Association for Cancer Research Meeting
2. Nventa Announces Positive Interim Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial
3. NanoBio Corporation Completes Interim Analysis of Phase 2 Clinical Trial in Onychomycosis
4. Independent Data Safety Monitoring Board Recommends Continuation of Sangarts Pivotal Phase III Trials of Hemospan(R) Following Second Interim Review
5. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
6. NanoBio Corporation Presents Preclinical and Interim Clinical Data on Topical Treatments for Herpes Labialis and Onychomycosis at AAD 2008
7. Interim Analysis Supports Continuation of Cell Genesys VITAL-1 Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer
8. Interim Safety Analysis Supports Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma
9. Novavax Announces Favorable Interim Results from Human Clinical Trial for Its Pandemic Influenza Vaccine Program
10. Grantees of the Avon Foundation Breast Cancer Prevention Research Initiative Gather in Houston to Report Interim Findings
11. Leading Physicians Present Interim Results from Multi-Center Studies of VNUS ClosureFAST Catheter at VEITHsymposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... Calif. , July 28, 2014 ... leader in lifestyle healthcare and subsidiary ... that it has acquired Physician Recommended Nutriceuticals (PRN) ... omega-3s, and related products for dry ... Plymouth Meeting, PA, in a transaction worth up ...
(Date:7/28/2014)...  ResMed (NYSE: RMD ), an innovator ... sleep-disordered breathing and other chronic respiratory conditions, has won ... against Taiwanese medical device manufacturer APEX Medical Corp. (APEX), ... 210 and 220 masks.  The judgment was entered by ... , is appealable, and applies throughout Germany.  ...
(Date:7/28/2014)... CHAPEL HILL, N.C. , July 28, 2014 /PRNewswire/ ... results of a clinical trial demonstrating that CXL-1427, a ... was well tolerated in healthy volunteers. The company has ... failure in a Phase IIa clinical trial designed to ... as its dosing levels. The Phase I ...
Breaking Medicine Technology:ALPHAEON Acquires PRN, A Leading Specialty Nutriceutical Company 2ALPHAEON Acquires PRN, A Leading Specialty Nutriceutical Company 3ResMed Receives Permanent Injunction against APEX in Germany, Continues Enforcement of Patents in Europe 2Cardioxyl Pharmaceuticals Successfully Completes First Clinical Trial For Heart Failure Drug CXL-1427 2
... Delaware, October 10, 2011 As the ... gigabytes of health and health-related technology information, and the ... providers are going to adopt new patterns to successfully ... reimbursement processes. In order to cope with ...
... Pharma, Inc. (Zosano) and Asahi Kasei Pharma Corporation (AKP) ... strategic collaboration for the development, commercialization and supply of ... AKP,s formulation of human parathyroid hormone (human PTH 1-34), ... risk of fracture.  Under the terms ...
Cached Medicine Technology:MedicalBillersandCoders.com Registers a Surge in Outsourcing of Physicians' Billing Requirements 2MedicalBillersandCoders.com Registers a Surge in Outsourcing of Physicians' Billing Requirements 3MedicalBillersandCoders.com Registers a Surge in Outsourcing of Physicians' Billing Requirements 4Zosano Pharma, Inc. and Asahi Kasei Pharma Corporation Enter Exclusive Licensing Agreement for a Weekly Transdermal Patch Formulation of Teribone™ (teriparatide acetate) for Osteoporosis 2Zosano Pharma, Inc. and Asahi Kasei Pharma Corporation Enter Exclusive Licensing Agreement for a Weekly Transdermal Patch Formulation of Teribone™ (teriparatide acetate) for Osteoporosis 3Zosano Pharma, Inc. and Asahi Kasei Pharma Corporation Enter Exclusive Licensing Agreement for a Weekly Transdermal Patch Formulation of Teribone™ (teriparatide acetate) for Osteoporosis 4
(Date:7/29/2014)... Seattle, Wa (PRWEB) July 29, 2014 Gout ... standards of lifestyles have proven that last statement essentially ... However, what many people still do not have are the ... not only is it costly to maintain treatment for it, ... hamper one’s daily activities to a grinding halt. ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 Consilium Staffing, Your ... year-over-year at the halfway point of 2014, with strong indications ... the second half of this year. , “This is a ... Vice President of Consilium Staffing. , “We are proud ... the year, but we are even more excited about how ...
(Date:7/29/2014)... Guests at Napa Valley's quintessential luxury resort, ... sleep experience. The top of each luxurious resort bed is ... These expertly crafted, 100% Egyptian cotton white duvets and pillow ... upon closer look, words are woven in the linens that ... , Intentional breathing and visualization are keys to ...
(Date:7/29/2014)... 29, 2014 A Forever Recovery , ... off to a great start and gives them a solid ... sponsor of the National Cherry Festival kickoff concert held on ... which was co-sponsored by Miller Lite and in partnership with ... Pepsi Bay Side Music Stage presented by Blue Cross Blue ...
(Date:7/29/2014)... Recently, Stwd.co.uk, a distinguished online supplier of special ... dresses . As a summer special offer, all these new ... percent off. All new and old customers can enjoy the ... to announce the new evening outfits. They want to bring ... happy to launch the big sale. Our cheap evening dresses ...
Breaking Medicine News(10 mins):Health News:Gout Natural Remedy Report Review | The Ultimate Secret to Eliminating Gout Naturally – Vinamy.com 2Health News:Consilium Staffing Experiences Significant Revenue Growth 2Health News:Auberge Du Soleil Offers INTENTIONS™ by Peacock Alley on Guests' Beds Providing a Unique Sleep Experience 2Health News:A Forever Recovery Sponsors National Cherry Festival Kickoff Concert Featuring Collective Soul on July 5 in Traverse City, MI 2Health News:Cheap Prom Dresses Available At Popular Online Store Stwd.co.uk 2
... ... , ... 22, 2010 -- DonJoy Velocity ankle braces were the best selling ankle brace ... ankle braces were double that of other ankle supports sold on the site., , , ...
... finds people are more likely to strike forefoot first, easing impact ... $100 on a fancy pair of running shoes, this news may ... for your body because of the way your feet land on ... course. Even so, "the way barefoot runners use their feet and ...
... ... months, numerous prominent politicians along with TV stars and sports heroes have made headline ... supporters cannot seem to get enough of the tawdry details of the betrayers, the ... lives. The true heroes are left standing in the shadows of their betrayers. ...
... , CALIFANO CONTINUES AS CHAIRMAN , ... Addiction and Substance Abuse (CASA) at Columbia University announced today ... Edmund S. Muskie School of Public Service, will become President ... succeeding Joseph A. Califano, Jr. , the former U.S. Secretary of ...
... , , NEW YORK , Jan. 27 ... $250,000 grant to the Clinton Health Access Initiative (CHAI), a ... in 2002. The grant will ensure the continuation of HIV/AIDS ... of the devastating January 12 earthquake. , ...
... or the woman who suggests using a condom makes no ... the woman suggests it makes a difference. If she highlights ... an erotic and fun activity, other women judge her more ... a condom or shares her concerns about sexually transmitted infections. ...
Cached Medicine News:Health News:DonJoy Velocity Ankle Brace is the Best Selling Ankle Brace in 2009 2Health News:Barefoot Best for Running? 2Health News:Barefoot Best for Running? 3Health News:The True Hero Stands in the Shadow of the Betrayer 2Health News:William H. Foster Succeeds Califano as President and CEO of CASA* 2Health News:William H. Foster Succeeds Califano as President and CEO of CASA* 3Health News:William H. Foster Succeeds Califano as President and CEO of CASA* 4Health News:Ford Foundation Commits $250,000 to Support HIV/AIDS Services in Haiti 2Health News:Condom or no condom? It's not what you say, it's how you say it 2
Drew Scientific has been making leading edge and top quality CBC systems for over 15 years.,The Excell 16/18 offers a reliable alternative for a 3 part differential....
... therapeutic, expandable turning surface for the BariMaxx™ ... Prevention and treatment of pressure ulcers, Large ... patients using a statuc mattress that would ... whose body weight and size pose a ...
... full-featured healthcare bed system providing a comfortable, ... management of larger patients, ,INDICATIONS: ,Large ... patients at risk for pressure ulcers, ... lbs. (including accessories), ,PRECAUTION: ,Side Rails ...
... beds feature folding head end and foot end deck ... head end and foot end deck panels folded the ... 67". This compact length makes storage, delivery and pick ... is not available on Model 4748B, Basic Maxi Rest ...
Medicine Products: